Renal outcomes in valve-in-valve transcatheter versus redo surgical aortic valve replacement

Autor:	Arian Arjomandi Rad, Vinci Naruka, Robert Vardanyan, Mohammad Yousuf Salmasi, Panagiotis T. Tasoudis, Simon Kendall, Roberto Casula, Thanos Athanasiou
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Pulmonary and Respiratory Medicine Heart Valve Prosthesis Implantation Reoperation Stroke/etiology Aortic Valve Stenosis Acute Kidney Injury Stroke Transcatheter Aortic Valve Replacement Treatment Outcome Risk Factors Aortic Valve Transcatheter Aortic Valve Replacement/adverse effects Humans Surgery Cardiology and Cardiovascular Medicine Aortic Valve/surgery Acute Kidney Injury/epidemiology Heart Valve Prosthesis Implantation/adverse effects
Zdroj:	Journal of Cardiac Surgery. 37(11):3743-3753
ISSN:	0886-0440
DOI:	10.1111/jocs.16890
Popis:	INTRODUCTION: Postoperative acute kidney injury (AKI) and the requirement for renal replacement therapy (RRT) remain common and significant complications of both transcatheter valve-in-valve aortic valve replacement (ViV-TAVR) and redo surgical aortic valve replacement (SAVR). Nevertheless, the understanding of renal outcomes in the population undergoing either redo SAVR or ViV-TAVR remains controversial. METHODS: A systematic database search with meta-analysis was conducted of comparative original articles of ViV-TAVR versus redo SAVR in EMBASE, MEDLINE, Cochrane database, and Google Scholar, from inception to September 2021. Primary outcomes were AKI and RRT. Secondary outcomes were stroke, major bleeding, pacemaker implantation rate, operative mortality, and 30-day mortality. RESULTS: Our search yielded 5435 relevant studies. Eighteen studies met the inclusion criteria with a total of 11,198 patients. We found ViV-TAVR to be associated with lower rates of AKI, postoperative RRT, major bleeding, pacemaker implantation, operative mortality, and 30-day mortality. No significant difference was observed in terms of stroke rate. The mean incidence of AKI in ViV-TAVR was 6.95% (±6%) and in redo SAVR was 15.2% (±9.6%). For RRT, our data showed that VIV-TAVR to be 1.48% (±1.46%) and redo SAVR to be 8.54% (±8.06%). CONCLUSION: Renoprotective strategies should be put into place to prevent and reduce AKI incidence regardless of the treatment modality. Patients undergoing re-intervention for the aortic valve constitute a high-risk and frail population in which ViV-TAVR demonstrated it might be a feasible option for carefully selected patients. Long-term follow-up data and randomized control trials will be needed to evaluate mortality and morbidity outcomes between these 2 treatments.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe8a62710d742a7ca2ac9e51029a671 https://doi.org/10.1111/jocs.16890 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.